openPR Logo
Press release

Non-Alcoholic Steatohepatitis Market Competitiveness Report 2025: Allergan, Cadila, Gemphire, Conatus

02-12-2019 12:27 PM CET | Health & Medicine

Press release from: Allied Market Research

/ PR Agency: Allied Market Research
Non-Alcoholic Steatohepatitis Market Competitiveness Report

Nonalcoholic steatohepatitis (NASH) is a common liver disease, often called silent liver disease. It is asymptomatic until its last stages, so many patients are unaware of their condition. It is projected that NASH will lead the cause of liver transplantation in the US UU In the next years. Some important factors, such as the higher prevalence of NASH, the expected release of drugs in processing and the greater number of unmet needs drive the growth of this market.

However, the poor diagnosis of NASH due to the lack of ideal diagnostic technologies limits the growth of the NASH market. According to Allied Market Research the global non-alcoholic steatohepatitis (NASH) market was valued at $1,179 million in 2017, and is expected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Get Access to TOC / Sample Report @ https://www.alliedmarketresearch.com/request-sample/224?utm_source=openpr_ss

Currently, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to treating patients with NASH. Depending on the type of drug, the market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor and selonsertib and cenicriviroc. The segment of vitamin E and pioglitazone contributes mainly due to the effectiveness in the treatment of steatosis, inflammation, infiltration of hepatocytes and healing in patients with NASH.

According to the sales channel, the market is segmented into hospital pharmacy, online provider and retail pharmacy. Currently, the retail pharmacy segment is a significant revenue generator, and it is estimated that it shows a predominance during the forecast period due to the convenience of the patient and the strong presence of retail pharmacies throughout the world. However, it is projected that the online provider segment will exhibit the fastest growth in the market due to the increase in knowledge of online pharmacies and the increased preference for online purchase of drugs instead of traditional methods.

Send Enquiry on this Report @ https://www.alliedmarketresearch.com/purchase-enquiry/224?utm_source=openpr_ss

Major Companies:

• Allergan plc.
• Cadila Healthcare Limited
• Conatus Pharmaceuticals Inc.
• Galmed Pharmaceuticals Ltd
• Gemphire Therapeutics Inc.

Key Findings of the Non-alcoholic Steatohepatitis (NASH) Market:

• Depending on the type of drug, the selonsertib and cenicriviroc segment is expected to exhibit the fastest growth on the market, it is projected to grow to a CAGR of 73.7% from 2021 to 2025.

• According to the sales channel, the retail pharmacy segment had more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.

• Based on the sales channel, the online provider segment exhibited the fastest growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025.

• According to the region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 62.62% during the forecast period.

Browse More Information of Report @ https://www.alliedmarketresearch.com/press-release/global-non-alcoholic-steatohepatitis-NASH-market-is-expected-to-reach-1-6-billion-by-2020-allied-market-research.html

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Alcoholic Steatohepatitis Market Competitiveness Report 2025: Allergan, Cadila, Gemphire, Conatus here

News-ID: 1580597 • Views: 311

More Releases from Allied Market Research

North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently

All 5 Releases


More Releases for NASH

NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
Overview of NASH - Opportunity Analysis and Forecasts to 2026
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation
Nonalcoholic Steatohepatitis (NASH) Syndrome - Opportunity Analysis and Forecast …
First described in 1980, Nonalcoholic Steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nonalcoholic Steatohepatitis (NASH) Market Worth US$ 20.0 Billion by 2025
New York, December 12: Market Research Engine has published a new report titled as “Non-Alcoholic Steatohepatitis (NASH) Market by Therapeutics (GFT505, Obeticholic Acid (INT-747), Liraglutide (Victoza) and Simtuzumab, Vitamin E, Pioglitazone, Placebo) - Global Industry Analysis, Trends and Forecast 2016 - 2025” Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025. Browse Full